Gilead Sciences
Manufacturing · California, United States · 10K+ Employees
View Company Info for Free
Overview
Headquarters
333 Lakeside Dr, Foster City, California...Phone Number
(650) 574-3000Website
www.gilead.comRevenue
$30.5 BillionStock Symbol
GILDIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
3
3
3
2
1
1
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, InRead more
Gilead Sciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Gilead Sciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Gilead Sciences recently announced quarterly report
Gilead Sciences, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Gilead Sciences is spiking on competitors!
Check if Gilead Sciences has recently received funding, and reach out quickly before it becomes old news!
Click to see if Gilead Sciences had a recent Job posting/layoffs
Product Launch: Get notified when Gilead Sciences launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Gilead Sciences
Funding: Get notified immidiatlly once Gilead Sciences has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Products Owned by Gilead Sciences
Gild
Explore company insights
Get a deeper look into Gilead Sciences's structure, leadership, and market position:
Company Profile Activity
Activity Insights
Gilead Sciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Gilead Sciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Gilead Sciences.
Gilead Sciences financials insights
Gather financial insights about Gilead Sciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
1992
Stock Offering
$86.3M
2024
Other Financing Round
$210M
Gilead Sciences Tech Stack
A closer look at the technologies used by Gilead Sciences
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Left Company
Executive Move
Executive Moves, Left Company
Open Position
Person-Based
Public Health
Open Position
Gilead Sciences News & Media
Gilead Sciences Eyes HIV, Oncology Catalysts as Pipeline Enters Execution Mode
Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined the company’s priorities across HIV, oncology and inflammation at the Wells Fargo conference, describing a portfolio that has expanded through internal development and acquisitions and is now entering a period of prioritizatAssembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program
– Assembly Bio to share 40% of U.S. development costs and profits for helicase-primase inhibitor program for recurrent genital herpes –Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
– Brings Together Oncology, Inflammation and Research Data Science Teams to Foster Scientific Collaboration – – One of Three Foster City Projects Supporting Gilead’s $32 Billion U.S. Investment and 3,000 High-Quality Domestic Jobs – Gilead Sciences, Inc. (Nasdaq: GILD) today celebrated the opening of its 182,000-square-foot Research Center at its Foster City headquarters, expanding capabilities in oncology, inflammation and research data science to advance medicines for some of the world’s mostGilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?
Gilead Sciences is branching out beyond its HIV franchise into oncology and immunology therapies.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Gilead Sciences
Sign Up For FreeTo access detailed company insights
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Vek... Read More
